BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
60.57
+0.14 (0.23%)
At close: Mar 5, 2026, 4:00 PM EST
61.00
+0.43 (0.71%)
After-hours: Mar 5, 2026, 7:48 PM EST
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 87.38, with a low estimate of 55 and a high estimate of 119. The average target predicts an increase of 44.26% from the current stock price of 60.57.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 5 | 4 |
| Buy | 9 | 9 | 8 | 8 | 7 | 8 |
| Hold | 7 | 5 | 6 | 6 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 19 | 19 | 20 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $80 → $105 | Buy | Maintains | $80 → $105 | +73.35% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $55 | Hold | Reiterates | $55 | -9.20% | Mar 2, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $98 → $104 | Strong Buy | Maintains | $98 → $104 | +71.70% | Feb 26, 2026 |
| Bernstein | Bernstein | Buy Maintains $90 → $94 | Buy | Maintains | $90 → $94 | +55.19% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $106 → $86 | Strong Buy | Maintains | $106 → $86 | +41.98% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
3.65B
from 3.22B
Increased by 13.34%
Revenue Next Year
4.07B
from 3.65B
Increased by 11.42%
EPS This Year
4.68
from 1.80
Increased by 159.19%
EPS Next Year
5.62
from 4.68
Increased by 20.22%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.1B | 4.8B | |||
| Avg | 3.7B | 4.1B | |||
| Low | 3.3B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.9% | 32.7% | |||
| Avg | 13.3% | 11.4% | |||
| Low | 1.6% | -10.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.34 | 9.18 | |||
| Avg | 4.68 | 5.62 | |||
| Low | 3.04 | 3.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 251.4% | 96.2% | |||
| Avg | 159.2% | 20.2% | |||
| Low | 68.3% | -19.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.